Federal contractors / RAYTHEON COMPANY

Federal contract award

N0001919C0079

MST PHASE 2 INTEGRATION AND TEST

Research the contractorView USAspending sourceSave to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

FieldReported value
AgencyDepartment of Defense
OfficeNAVAL AIR SYSTEMS COMMAND
NAICS336414 — Guided Missile and Space Vehicle Manufacturing
PSC1420 — Guided Missile Components
Parent award / vehicleNot reported
Set-asideNO SET ASIDE USED.
Pricing typeCOST PLUS INCENTIVE FEE
Obligations$831.1M
Current contract value$849.3M
Potential contract value / ceiling$900.2M
Start dateAug 28, 2019
Current end dateDec 31, 2027
Potential end dateDec 31, 2027
Latest award activityJun 1, 2026
Source loadedSep 19, 2026

Funding and modification history

Showing the latest 90 of 90 loaded transactions. Negative values are deobligations.

DateModificationObligation changeDescription
Jun 1, 2026P00050$50.5MTHE PURPOSE OF THIS MODIFICATION IS TO INCREASE THE COST ON CLINS 0001, 1001, AND 3007 TO FUND COST OVERRUNS, PROVIDE INCREMENTAL FUNDING FOR CLIN 0007, AND UPDATE EXHIBIT A CDRLS.
May 21, 2026A00044$0UNDEFINITIZED ORDER
May 21, 2026A00045$0UNDEFINITIZED ORDER
Mar 16, 2026A00043$0UNDEFINITIZED ORDER
Feb 5, 2026P00049$0THIS MODIFICATION EXTENDS THE PERIOD OF PERFORMANCE (POP) OF CLIN 0001 FROM 28 FEBRUARY 2026 TO 30 SEPTEMBER 2026.
Jan 22, 2026P00048$5.0MTHIS MOD ESTABLISHES CLIN 0009 PASSIVE SENSOR WITH AN NTE OF $5,000,000. THIS IS A DIRECTED CHANGE TO THE PASSIVE SENSOR TO UPDATE THE DESIGN PER THE UPDATED ATT (1) SOW.
Dec 18, 2025P00047$8.0MTHE PURPOSE OF THIS MODIFICATION IS TO ADD INCREMENTAL FUNDING TO CLIN 0007 IN THE AMOUNT $8,000,000 AND UPDATE CLAUSE 5252.232-9516.
Dec 10, 2025P00046$7.6MTHE PURPOSE OF THIS MODIFICATION IS TO: 1. ADD OVERRUN FUNDING TO CLIN 0001. 2. UPDATE SECTION I TO ADD CLAUSE 252.225-7013 3. UPDATE SECTION J TO UPDATE ATTACHMENT 1.
Oct 28, 2025P00045$1.7MTHE PURPOSE OF THIS MODIFICATION IS TO PROVIDE OVERRUN FUNDING ON CLIN 1001 AND UPDATE SECTION E.
Oct 7, 2025A00042$0UNDEFINITIZED ORDER
Sep 26, 2025P00044$32.6MTHIS MODIFICATION ADDS CLIN 0007 ULTRA 1.1+ AND CLIN 0008 RO HIL, EXTENDS THE PERIOD OF PERFORMANCE (POP) FOR CLINS 0001 AND 0002, ADDS CLIN 3006 TO PROVIDE OVERRUN FUNDING FOR CLIN 3004, AND ADDS CLIN 3007 TO PROVIDE OVERRUN FUNDING FOR CLIN 3001.
Aug 6, 2025P00043$4.3MTHE PURPOSE OF THIS MODIFICATION IS TO ADD FUNDING TO COVER COST OVERRUNS TO CLIN 1001.
May 20, 2025P00042$0THE PURPOSE OF THIS MODIFICATION IS TO INCREASE THE NTE ON CLIN 0001 ASSOCIATED WITH THE ULTRA 1.2 CHANGE ORDER, EXTEND THE PERIOD OF PERFORMANCE ON CLIN 3002 AND 3003, UPDATE ATTACHMENT 9, AND UPDATE EXHIBIT A.
May 8, 2025A00041$0UNDEFINITIZED ORDER
Apr 10, 2025P00041$0THE PURPOSE OF THIS NO COST MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE ON CLIN 0006.
Mar 14, 2025P00040$15.2MTHE PURPOSE OF THIS MODIFICATION IS TO ADD INCREMENTS OF FUNDING AS A RESULT OF A COST OVERRUN TO CLIN 0001.
Feb 20, 2025P00039$15.3MTHE PURPOSE OF THIS MODIFICATION IS TO UPDATE THE TEMPLATE TO SHOW THE UNIT OF MEASURE ON CLIN 3005 FOR CONTRACTOR ACQUIRED PROPERTY AND INCREASE THE COST ON CLIN 1001 TO FUND A COST OVERRUN.
Oct 31, 2024P00038$0THE PURPOSE OF THIS ADMINISTRATIVE MODIFICATION IS TO UPDATE THE ATTACHMENT 9 HARDWARE LIST INCLUDED ON THE REFERENCE CONTRACT.
Sep 25, 2024A00040$0MST PHASE 2 INTEGRATION AND TEST
Sep 20, 2024P00037$150.0KTHE PURPOSE OF THIS MODIFICATION IS TO ADD OVERRUN FUNDING TO CLIN 1001.
Aug 30, 2024P00036$14.1MTHE PURPOSE OF THIS MODIFICATION IS TO FUND AN OVERRUN ON CLINS 0001 AND 1001, UPDATE THE POP ON CLINS 0001 AND 0002, UPDATE EXHIBIT A AND ATTACHMENT 9, AND UPDATE CLAUSE 5252.232-9516.
Jul 17, 2024A00039$0MST PHASE 2 INTEGRATION AND TEST
Jun 20, 2024P00035$37.4MTHE PURPOSE OF THIS MODIFICATION IS TO ADD INCREMENTS OF FUNDING AS A RESULT OF OVERRUNS TO CLINS 0001 AND 1001. THIS MODIFICATION ALSO INCLUDES AN UPDATE TO THE STATEMENT OF WORK AND OTHER ADMINISTRATIVE CHANGES.
Apr 4, 2024P00034$10.7MADDS INCREMENTAL AND OVERRUN FUNDING ALONG WITH MAKING ADMINISTRATIVE UPDATES
Jan 25, 2024P00033$28.8MACTION ADDS INCREMENTAL AND OVERRUN FUNDING AND UPDATES THE GFP LIST.
Oct 31, 2023P00032$14.0MADDS FUNDING FOR COST OVERRUN. IN ADDITION, INCREASED CLIN 0001 AS A RESULT OF INCORPORATING THE FLY BY JULY EFFORT.
Sep 15, 2023P00031$14.1MTHE PURPOSE OF THIS MODIFICATION IS TO ADD INCREMENTS OF FUNDING AS A RESULT OF OVERRUNS FOR CLIN 0001 AND 1001. THIS MODIFICATION ALSO INCLUDES UPDATING ATTACHMENT 1 SOW AND EXHIBIT A.
Aug 1, 2023P00030$124.3MTHE PURPOSE OF THIS MODIFICATION IS TO PROCURE MARITIME STRIKE TOMAHAWK'S (MST) LOW RATE PRODUCTION (LRP) 3 FOR A QUANTITY OF 42 MST SEEKER SUITES.
Jul 19, 2023P00029$4.0MTHE PURPOSE OF THIS MODIFICATION IS TO CHANGE THE ULTRA FUNCTIONAL SPECIFICATION PERFORMED ON CLIN 0001.
Jun 20, 2023P00028$5.8MTHE PURPOSE OF THIS MODIFICATION IS TO ADD FUNDING AND UPDATE ATTACHMENTS.
Jun 16, 2023A00038$0MST PHASE 2 INTEGRATION AND TEST
May 31, 2023A00037$0MST PHASE 2 INTEGRATION AND TEST
May 22, 2023A00036$0MST PHASE 2 INTEGRATION AND TEST
Apr 3, 2023A00035$0MST PHASE 2 INTEGRATION AND TEST
Mar 24, 2023A00023$0MST PHASE 2 INTEGRATION AND TEST
Feb 27, 2023P00027$16.0MTHE PURPOSE OF THIS MODIFICATION IS TO INCREMENTALLY FUND CLIN 0001.
Jan 23, 2023P00026$9.9MTHE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE POP AND ADD FUNDING TO INCLUDE THE JOINT FLIGHT TEST ADJUSTMENT.
Dec 1, 2022A00027$0MST PHASE 2 INTEGRATION AND TEST
Nov 17, 2022P00025$13.7MTHE PURPOSE OF THIS MODIFICATION IS TO ADD/FUND CLINS.
Sep 28, 2022P00024$807.7KINCREMENTAL FUNDING
Sep 1, 2022A00026$0MST PHASE 2 INTEGRATION AND TEST
Sep 1, 2022P00023$6.7MINCREMENTAL FUNDING
Jun 14, 2022A00014$0MST PHASE 2 INTEGRATION AND TEST
Jun 14, 2022P00022$14.3MINCREMENTALLY FUND, CONSIDERATION, SOW, GFP, CDRL UPDATES.
Jun 8, 2022A00025$0MST PHASE 2 INTEGRATION AND TEST
May 3, 2022A00024$0MST PHASE 2 INTEGRATION AND TEST
Mar 25, 2022P00021$40.4MLRP2 FY22 OPTION EXERCISE
Mar 7, 2022P00020$7.8MFY22 INCREMENTAL FUNDING MODIFICATION.
Feb 22, 2022P00019$16.6MUPDATE ATTACHMENTS & INCREMENTALLY FUND
Dec 10, 2021A00022$0MST PHASE 2 INTEGRATION AND TEST
Dec 9, 2021P00018$0CHANGE ORDER - SPEC CHANGE
Dec 7, 2021P00017$207.4KALTERNATE FREQUENCY DUAL SALVO ENGINEERING STUDY.
Dec 1, 2021A00021$0MST PHASE 2 INTEGRATION AND TEST
Oct 29, 2021P00016$36.6MADD FY21-22 LRP SCOPE & RDT&E INCREMENTAL FUNDS.
Oct 20, 2021A00020$0MST PHASE 2 INTEGRATION AND TEST
Sep 28, 2021P00015$314.1KINCREMENTAL FUNDING & UPDATE GFP LIST
Sep 22, 2021A00018$0MST PHASE 2 INTEGRATION AND TEST
Sep 22, 2021A00019$0MST PHASE 2 INTEGRATION AND TEST
Aug 25, 2021A00017$0MST PHASE 2 INTEGRATION AND TEST
Aug 19, 2021P00014$757.1KINCREMENTAL FUNDING
Aug 5, 2021A00016$0MST PHASE 2 INTEGRATION AND TEST
Jul 9, 2021P00013$300.0KEXTEND POP FROM 28FEB2023 TO 29SEPT2023 UPDATE CLAUSE 52522019500 SPECIAL H1 SOFTWARE AUTHORIZATION CONTRACT CLAUSE UPDATE ATTACHMENT 1 SOW ADDITION OF CLIN 0004 ATTACHMENT 5 GFP ATTACHMENT 8 RMD SUB PLAN
Jun 17, 2021A00015$0MST PHASE 2 INTEGRATION AND TEST
Mar 18, 2021A00012$0MST PHASE 2 INTEGRATION AND TEST
Mar 5, 2021A00011$0MST PHASE 2 INTEGRATION AND TEST
Feb 24, 2021P00012$74.2MINCREMENTALLY FUND
Feb 19, 2021A00010$0MST PHASE 2 INTEGRATION AND TEST
Jan 15, 2021P00011$17.1MINCREMENTALLY FUND CLIN 0001.
Dec 14, 2020P00010$2.3MINCREMENTAL FUNDING, UPDATE CSDR & GFP ATTACHMENTS, ADD BILLING INSTRUCTIONS.
Dec 2, 2020A00009$0MST PHASE 2 INTEGRATION AND TEST
Dec 2, 2020A00013$0MST PHASE 2 INTEGRATION AND TEST
Oct 26, 2020A00008$0MST PHASE 2 INTEGRATION AND TEST
Sep 23, 2020P00009$873.0KINCREMENTAL FUNDING
Sep 9, 2020P00008$2.0MADD INCREMENTAL FUNDING, UPDATE RENT FREE USE CLAUSE, UPDATE SOW, AND UPDATE GFP LIST.
Aug 4, 2020P00007$597.7KINCREMENTAL FUNDING
Jul 9, 2020A00007$0MST PHASE 2 INTEGRATION AND TEST
Jun 23, 2020ARZ999$0MST PHASE 2 INTEGRATION AND TEST
Jun 10, 2020P00006$4.7MINCREMENTAL FUNDING, RENT-FREE USE UPDATE, DATA ASSERTION UPDATE, SPECIFICATION DOCUMENT APPLICABILITY
May 6, 2020A00006$0MST PHASE 2 INTEGRATION AND TEST
Apr 28, 2020P00005$0CDRL UPDATE
Mar 10, 2020P00004$106.0MINCREMENTAL FUNDING, CDRL UPDATE, RENT-FREE USE CLAUSE UPDATE
Feb 18, 2020A00005$0MST PHASE 2 INTEGRATION AND TEST
Feb 6, 2020P00003$16.0MINCREMENTAL FUNDING, CDRL UPDATE, GFP UPDATE, CDR CORRECTION
Jan 21, 2020P00002$0UPDATE CDRL DELIVERIES
Jan 8, 2020A00004$0MST PHASE 2 INTEGRATION AND TEST
Dec 19, 2019P00001$1.6MTHE PURPOSE OF THIS EFFORT IS TO: INCREMENTALLY FUND, UPDATE CDRLS AND CSDR PLAN, ADD LANGUAGE TO SECTION C ON SCG, UPDATE VARIOUS CLAUSES, AND CHANGE THE SURVEILLANCE LEVEL FROM C TO B.
Dec 17, 2019A00003$0MST PHASE 2 INTEGRATION AND TEST
Nov 21, 2019A00002$0MST PHASE 2 INTEGRATION AND TEST
Nov 18, 2019A00001$0MST PHASE 2 INTEGRATION AND TEST
Aug 28, 20190$44.6MMST PHASE 2 INTEGRATION AND TEST

Estimated positioning window

Dec 31, 2026 – Jun 30, 2027

Recompete signal:
70/100

Why this recompete signal

Contract timing and recorded acquisition signals at the time of calculation.

Stored score: 70/100. Available recorded signals: 65 points.

Contract end 2027-12-31 (425 days from calculation)
+25 points
24 historical awards in this buyer and category group
+15 points
90 recorded award transactions
+10 points
Latest award action: 2026-06-01
+5 points
Parent award identifier recorded
+0 points
Solicitation identifier recorded
+10 points
Linked official forecast
+0 points
Calculated on
2026-11-01 10:17:53.997580+00:00

The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.

Rule-based research score; it does not measure your chance of winning.

This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.

USAspending award record

. Rule-based research score; positioning dates are estimates.

Recompete score calculated Nov 1, 2026.

Research next steps

  1. Check the linked forecast or SAM for a confirmed solicitation and current timing.
  2. Check the stated set-aside against the solicitation and current certifications.
  3. Review the award scope and buyer evidence before making a bid/no-bid decision.